人血白蛋白与人工胶体对肝硬化腹水患者引流后疗效比较的Meta分析

杨君; 宁琪琪; 吴静; 李娟; 朱跃科; 于红卫; 孟庆华; 胡中杰

doi:10.3969/j.issn.1001-5256.2019.01.015

人血白蛋白与人工胶体对肝硬化腹水患者引流后疗效比较的Meta分析

DOI: 10.3969/j.issn.1001-5256.2019.01.015

首都医科大学附属北京佑安医院重症肝病科

基金项目:

北京丰台区卫生计生系统科学研究项目(2017-60)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1603
- HTML全文浏览量: 19
- PDF下载量: 321
- 被引次数: 0
出版历程
- 收稿日期: 2018-08-29
- 出版日期: 2019-01-20

Clinical effect of human serum albumin versus artificial colloidal fluid in patients with cirrhotic ascites undergoing drainage:A Meta-analysis

Department of Severe Liver Disease, Beijing YouAn Hospital, Capital Medical University

Research funding:

摘要

摘要: 目的评估肝硬化合并腹水患者引流后输注白蛋白与人工胶体的疗效差别。方法计算机检索lochrane Library（1993年-2018年2月）、PubMed （1966年-2018年2月）、Embase （1990年-2018年2月）、中国期刊全文数据库（1994年-2018年2月）、中国生物医学文献数据库（1978年-2018年2月）、中文科技期刊数据库（1989年-2018年2月）、中华医学会数字化期刊库（1997年-2018年2月）,同时手检相关期刊和会议论文集,纳入有关肝硬化合并腹水患者腹水引流后输注白蛋白与人工胶体的的随机对照试验,按Jadad改良法Cochran系统评价方法提取资料、评价文献质量并进行统计学分析,数据采用RevMan5. 3软件进行Meta分析。结果共纳入7篇随机对照试验,共696例患者,其中人血白蛋白组299例,人工胶体组397例。Meta分析结果显示,白蛋白组低钠血症发生率低于人工胶体组,差异有统计学意义[11. 04%vs 20. 4%,相对危险度（RR）=0. 58,95%可信区间（95%CI）:0. 400. 84,P=0. 0...
- 肝硬化 /
- 腹水 /
- 白蛋白类 /
- 人工胶体 /
- Meta分析
Abstract: Objective To investigate the clinical effect of infusion of albumin versus artificial colloidal fluid after ascites drainage in patients with liver cirrhosis and ascites.Methods Cochrane Library (from 1993 to February 2018) PubMed (from 1966 to February 2018) , Embase (from 1990 to February 2018) , Chinese Scientific Journal Full-Text Database (from 1994 to February 2018) , CBM (from 1978 to February 2018) , China Science and Technology Journal Database (from 1989 to February 2018) , Chinese Medical Association Digital Periodical Database (from 1997 to February 2018) , and related periodicals and conference proceedings were searched for randomized controlled trials (RCTs) on infusion of albumin and artificial colloidal fluid after ascites drainage in patients with liver cirrhosis and ascites.The modified JADAD method and Cochrane systematic review were used for data extraction and literature quality assessment, and a statistical analysis was performed.RevMan 5.3 was used for the Meta-analysis.Results A total of 7 RCTs with 696 patients were included, with 299 patients in the human serum albumin group and 397 in the artificial colloidal fluid group.The human serum albumin group had a significantly lower incidence rate of hyponatremia than the artificial colloidal fluid group (11.04%vs 20.4%, risk ratio[RR]=0.58, 95%confidence interval[CI]:0.40-0.84, P=0.004) .There were no significant differences between the two groups in the incidence rates of kidney injury (7.02%vs 7.81%, RR=0.93, 95%CI:0.53-1.65, P=0.82) , hepatic encephalopathy (6.77%vs 7.45%, RR=0.87, 95%CI:0.48-1.55, P=0.63) , gastrointestinal bleeding (3.91%vs 3.65%, RR=0.97, 95%CI:0.43-2.22, P=0.95) , abdominal infection (5.22%vs 4.56%, RR=1.07, 95%CI:0.52-2.18, P=0.86) , and hospital death (12.78%vs 14.59%, RR=0.70, 95%CI:0.47-1.02, P=0.06) .ConclusionHuman albumin has an advantage over artificial colloidal fluid in reducing hyponatremia after ascites drainage in patients with cirrhotic ascites.
- liver cirrhosis /
- ascites /
- albumins /
- artificial colloid /
- Meta-analysis

HTML全文

参考文献(22)

[1]MOORE KP, AITHAL GP.Guidelines on the management of ascites in cirrhosis[J].Gut, 2006, 55 (Suppl 6) :1-12.

[2]RUNYON BA.Management of adult patients with ascites due to cirrhosis:An update[J].Hepatology, 2009, 49 (6) :2087-2107.

[3]European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.

[4]D'AMICO G, GARCIA-TSAO G, PAGLIARO L.Natural history and prognostic indicators of survival in cirrhosis:A systematic review of 118 studies[J].J Hepatol, 2006, 44 (1) :217-231.

[5]CHOLONGITAS E, PAPATHEODORIDIS GV, MANESIS EK, et al.Spontaneous bacterial peritonitis in cirrhotic patients:Is prophylactic propranolol therapy beneficial?[J].J Gastroenterol Hepatol, 2006, 21 (3) :581-587.

[6]JADAD AR, MOORE RA, CARROLL D, et al.Assessing the quality of reports of randomized clinical trials:Is blinding necessary?[J].Control Clin Trials, 1996, 17 (1) :1-12.

[7]HERNNDEZ PREZ RE, AGUILAR RAMREZ JR, HERNNDEZLPEZ JM, et al.Massive paracentesis and administration of dextran 70 vs albumin in cirrhotic patients with tense ascites[J].Rev Gastroenterol Mex, 1995, 60 (1) :22-26.

[8]BERTRN X, FERNNDEZ-BAARES F, PLANAS R, et al.Impact on the energetic-proteic nutritional status of total paracentesis combined with infusion of albumin or dextran-70 in the therapy of tension ascites in liver cirrhosis[J].Rev Esp Enferm Dig, 1991, 79 (5) :320-323.

[9]MOREAU R, VALLA DC, DURAND-ZALESKI I, et al.Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid:A randomised controlled pilot trial[J].Liver International, 2006, 26 (1) :46-54.

[10]ALTMAN C, BERNARD B, ROULOT D, et al.Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis[J].Eur J Gastroenterol Hepatol, 1998, 10 (1) :5-10.

[11]GINS A, FERNNDEZ-ESPARRACH G, MONESCILLO A, et al.Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis[J].Gastroenterology, 1996, 111 (4) :1002-1010.

[12]SALERNO F, BADALAMENTI S, LORENZANO E, et al.Randomized comparative study of hemaccel vs.albumin infusion after total paracentesis in cirrhotic patients with refractory ascites[J].Hepatology, 1991, 13 (4) :707-713.

[13]GARCA-COMPEAN D, BLANC P, LARREY D, et al.Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis:A randomized controlled trial[J].Ann Hepatol, 2002, 1 (1) :29-35.

[14]FASSIO E, TERG R, LANDEIRA G, et al.Paracentesis with Dextran70 vs.aracentesis wit albumin in cirr with tense ascites results of a randomized study[J].J Hepatol, 1992, 14 (2-3) :310-316.

[15]PLANAS R, GINS P, ARROYO V, et al.Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis[J].Gastroenterology, 1990, 99 (6) :1736-1744.

[16]XU LL, SU L, WANG C, et al.Therapcutic effects of tolvaptan on patients of cirrhosis, ascites complicated with hyponatremia[J/CD].Chin J Liver Dis:Electr Version, 2018, 10 (2) :87-90. (in Chinese) 徐力力, 苏良, 王晨, 等.托伐普坦治疗伴低钠血症肝硬化腹水患者的疗效[J/CD].中国肝脏病杂志:电子版, 2018, 10 (2) :87-90.

[17]Chinese Society of Hepatology, Chinese Medical Association.Guidelines on the management of ascites and complications in cirrhosis[J].J Clin Hepatol, 2017, 33 (10) :1847-1863. (in Chinese) 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南[J].临床肝胆病杂志, 2017, 33 (10) :1847-1863.

[18]RUIZ-DEL-ARBOL L, MONESCILLO A, JIMENEZ W, et al.Paracentesis-induced circulatory dysfunction:Mechanism and effect on hepatic hemodynamics in cirrhosis[J].Gastroenterology, 1997, 113 (2) :579-586.

[19]PREDESCU D, PREDESCU S, MALIK AB.Transport of nitrated albumin across continuous vascular endothelium[J].Proc Natl Acad Sci U S A, 2002, 99 (21) :13932-13937.

[20]SORT P, NAVASA M, ARROYO V, et al.Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis[J].N Engl JMed, 1999, 341 (6) :403-409.

[21]WU J, YIN F, LUO GH, et al.Association of hyponatremia with degree of liver injury and complications in patients with decompensated liver cirrhosis[J].J Clin Hepatol, 2017, 33 (2) :277-280. (in Chinese) 武健, 尹芳, 罗贯虹, 等.失代偿期肝硬化患者低钠血症与肝损伤程度及并发症的关系[J].临床肝胆病杂志, 2017, 33 (2) :277-280.

[22]WANG HQ, LIN Y, YAN Y.Clinical study on the significcance of hyponatremia in patients with cirrhotic ascites[J].J Clin Exp Med, 2017, 16 (22) :2275-2278. (in Chinese) 王慧卿, 林叶, 严艳.肝硬化腹水合并低钠血症的临床研究[J].临床和实验医学杂志, 2017, 16 (22) :2275-2278.

施引文献

资源附件(0)

访问统计